Stevanato's operating margin expanded from 10.8% in Q2 2024 to 17.6% in Q3 2026, with revenue reaching $324.2M in the latest quarter, suggesting mix-driven pricing power is taking hold in its pharmaceutical packaging business.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 3, 2026 | $0.18+1.4% vs $0.18 | $369M+1.7% vs $363M |
Q3 2026 Aug 4, 2026 | $0.16+10.5% vs $0.14 | $345M+1.3% vs $341M |
Q2 2026 May 7, 2026 | $0.13+8.3% vs $0.12 | $316M+1.8% vs $310M |
Q2 2026 Mar 4, 2026 | $0.21+5.0% vs $0.20 | $407M+4.0% vs $391M |
The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return for the Russell 2000 Growth Index. Small Cap Composite top 5 leaders include Repligen, Merit Medical, Stevanato Group, Descartes Systems and Digi International. Small Cap Composite bottom 5 laggards include Mercury Systems, AAON, RBC Bearings, SPX Technologies and UL Solutions.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable therapie.
The Sustainable Value Strategy trailed its benchmark, the Russell 2500 Value Index, in the third quarter. New positions include Lineage, Birkenstock, Matador Resources, KBR and ICON. InterDigital, Stevanato Group and Exelixis rounded out our top contributors.
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, November 3, 2026, to di.
Benchmark STVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Stevanato Group S.p.A. (STVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.57 | $3.7B | 23.79 | 3.21% | 11.24% | 9.07% | 0.43% | |
| $45.77 | $955.14M | 14.26 | 3.21% | 4.68% | 13.03% | 2.26% | |
| $174.43 | $5.6B | 32.70 | 8.75% | 15.41% | 13.21% | 0.5% | |
| $211.88 | $58.38B | 50.76 | -10.91% | 5.66% | 3.67% | 1.96% | |
| $399.81 | $28.14B | 44.31 | 6.26% | 18.81% | 21.08% | 0.21% | |
| $15.47 | $10.46B | 31.24 | -3.41% | 5.08% | 5.96% | — |
Stevanato Group S.p.A. (STVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when STVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Stevanato Group S.p.A. (STVN) stock FAQ — growth, dividends, profitability & financials explained
Stevanato Group S.p.A. (STVN) reported $1.24B in revenue over the trailing twelve months. Revenue was $1.14B in fiscal year 2025. That is 112% more than the $536.5M of fiscal year 2019.
Stevanato Group S.p.A. (STVN) grew revenue by 6.2% over the trailing twelve months, compared with the twelve months before.
Yes. Stevanato Group S.p.A. (STVN) earned $139.7M in net income over the trailing twelve months (a 11.2% net margin).
Yes. Stevanato Group S.p.A. (STVN) pays a dividend that yields 0.43% at the current price, a small yield.
Stevanato Group S.p.A. (STVN) had a return on equity (ROE) of 9.1% over the trailing twelve months. That is below the market's typical 10-15%.
Stevanato Group S.p.A. (STVN) had negative free cash flow of $0.1M over the trailing twelve months.
